Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02353598
Recruitment Status : Completed
First Posted : February 3, 2015
Last Update Posted : July 24, 2019
Sponsor:
Information provided by (Responsible Party):
Genentech, Inc.

Brief Summary:
This randomized, placebo-controlled, double-blind, parallel-arm study will evaluate the safety and tolerability of at least two dose levels of intravenous (IV) crenezumab in 24-72 participants with mild to moderate Alzheimer disease (AD) (mini-mental state examination [MMSE] 18 to 28 points, inclusive). An optional open-label extension (OLE) will be offered after the completion of initial double-blind stage.

Condition or disease Intervention/treatment Phase
Alzheimer Disease Drug: Crenezumab dose level 1 Drug: Crenezumab dose level 2 Drug: Crenezumb dose level 3 Drug: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 77 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase Ib, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Arm, Multiple-Dose Study to Assess The Safety, Tolerability, And Pharmacokinetics of Intravenous Crenezumab Administered in Patients With Mild to Moderate Alzheimer's Disease
Actual Study Start Date : February 26, 2015
Actual Primary Completion Date : November 30, 2016
Actual Study Completion Date : March 26, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Double-blind treatment window: Crenezumab dose level 1
Participants will recieve crenezumab dose level 1 once every 4 weeks.
Drug: Crenezumab dose level 1
Participants will receive crenezumb dose level 1 IV infusion once every 4 weeks up to Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.

Experimental: Double-blind treatment window: Crenezumab dose level 2
Participants will receive crenezumab dose level 2 once every 4 weeks.
Drug: Crenezumab dose level 2
Participants will receive crenezumb dose level 2 IV infusion once every 4 weeks up to Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.

Experimental: Double-blind treatment window: Crenezumab dose level 3
Participants will receive crenezumab dose level 3 once every 4 weeks.
Drug: Crenezumb dose level 3
Participants will receive crenezumb dose level 3 IV infusion once every 4 weeks upto Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.

Placebo Comparator: Double-blind treatment window: Placebo
Participants will receive placebo matched to crenezumab once every 4 weeks.
Drug: Placebo
Participants will receive placebo matched to crenezumab IV infusion once every 4 weeks upto Week 13 in double-blind treatment window.

Experimental: Optional OLE window: Crenezumab
Participants will receive crenezumab dose levels 1 2, or 3 once in every 4 weeks.
Drug: Crenezumab dose level 1
Participants will receive crenezumb dose level 1 IV infusion once every 4 weeks up to Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.

Drug: Crenezumab dose level 2
Participants will receive crenezumb dose level 2 IV infusion once every 4 weeks up to Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.

Drug: Crenezumb dose level 3
Participants will receive crenezumb dose level 3 IV infusion once every 4 weeks upto Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.




Primary Outcome Measures :
  1. Number of participants with anti-crenezumab antibodies [ Time Frame: From baseline up to follow-up period (Week 69) ]
  2. Number of participants with suicidal ideation, suicidal behavior, and self-injurious behavior without suicidal intent, as determined using the columbia-cuicide severity rating scale (C-SSRS) [ Time Frame: From baseline up to follow-up period (Week 69) ]
  3. Number of participants with changes from baseline in vital signs, electrocardiogram (ECG) and clinical laboratory results [ Time Frame: From baseline up to follow-up period (Week 69) ]
  4. Number of participants with amyloid-related imaging abnormalities-hemorrhage (ARIA-H) [ Time Frame: Up to Week 13 ]
  5. Number of participants with adverse events (AEs) and serious adverse events (SAEs) according to national cancer institute common terminology criteria for adverse events, version 4.0 (NCICTCAE v4.0) [ Time Frame: From baseline up to follow-up period (Week 69) ]
  6. Number of participants with of non-serious AEs of special interest [ Time Frame: From baseline up to follow-up period (Week 69) ]
  7. Number of participants with amyloid-related imaging abnormalities-edema/effusion (ARIA-E) [ Time Frame: Up to Week 13 ]

Secondary Outcome Measures :
  1. Serum concentration of crenezumab [ Time Frame: Pre-dose on Day 1, 60-90 minutes (min) post infusion on Day 1, Days 2, 8, Week 2, pre-dose and 60-90 min post infusion on dosing day of Weeks 5, 9, 13, and 21; pre-dose and 60-90 min post infusion on dosing day of Weeks 25, 53, 61, and 69 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Body weight greater than or equal (>/=) 45 kilograms (kg) and less than or equal (</=) 120 kg
  • Ages 50-90 years, inclusive
  • Availability of a person ("caregiver") who, in the investigator's judgment, has frequent and sufficient contact with the participant and is able to provide accurate information regarding the participant's cognitive and functional abilities, agrees to provide information at clinic visits, which require partner input for scale completion, and signs the necessary consent form
  • Willingness and ability to complete all aspects of the study; the participant should be capable of completing assessments either alone or with the help of the caregiver
  • Adequate visual and auditory acuity, in the investigator's judgment, sufficient to perform the neuropsychological testing
  • Clinical diagnosis of probable mild to moderate AD based on the national institute on neurological and communication disease and stroke/Alzheimer's disease and related disorders association (NINCDS/ADRDA) criteria or probable major neurocognitive disorder due to AD of mild to moderate severity based on diagnostic and statistical manual of mental disorders, version 5 (DSM-5) criteria
  • Screening MMSE score of 18-28 points, inclusive
  • Screening clinical dementia rating global score (CDR-GS) of 0.5 or 1.0
  • Screening geriatric depression (GDS)-15 score less than (<) 6
  • Positive florbetapir amyloid positron emission tomography (PET) scan by qualitative read conducted by the core/central PET laboratory
  • Women must be postmenopausal or surgically sterile
  • Men with female partners of childbearing potential agree to remain abstinent or use adequate methods of contraception as defined by protocol during the treatment period and for at least 8 weeks after the last dose of study drug and agreement to refrain from donating sperm during this same period

Exclusion Criteria:

  • History or presence of clinically evident vascular disease potentially affecting the brain that, in the opinion of the investigator, has the potential to affect cognitive function
  • History or presence of stroke within the previous 2 years or documented history of transient ischemic attack within the previous 12 months
  • History of severe, clinically significant central nervous system trauma
  • History or presence of intracranial tumor that is clinically relevant in the opinion of the investigator
  • Presence of infections that affect brain function or history of infections that resulted in neurologic sequelae
  • History or presence of systemic autoimmune disorders potentially causing progressive neurologic disease with associated cognitive deficits
  • History or presence of a neurologic disease other than AD that may affect cognition
  • Presence of superficial siderosis, more than four cerebral microhemorrhages, or evidence of a prior cerebral macrohemorrhage
  • Inability to tolerate magnetic resonance imaging (MRI) procedures or contraindication to MRI
  • History or presence of atrial fibrillation except if only one episode that resolved more than 1 year ago and for which treatment is no longer indicated or that in the investigator's judgment poses no risk for future stroke
  • Within the previous 2 years, unstable or clinically significant cardiovascular disease
  • Uncontrolled hypertension
  • Chronic kidney disease of Stage >/= 4, according to the national kidney foundation kidney disease outcomes quality initiative (NKF KDOQI) guidelines for chronic kidney disease
  • Impaired hepatic function
  • Clinically significantly abnormal screening blood or urine that remain abnormal on retest
  • History of malignancies within 5 years prior to screening, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or Stage I uterine cancer; cancer that is considered likely to be cured, is not being actively treated with anti-cancer therapy or radiotherapy and not likely to require treatment in the ensuing 5 years as well as cancers that are considered to have low probability of recurrence are allowed
  • Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins
  • Severe or unstable medical condition that, in the opinion of the investigator or sponsor, could be expected to progress, recur, or change to such an extent that it could put the patient at special risk, bias the assessment of the clinical or mental status of the patient to a significant degree, interfere with the patient's ability to complete the study assessments, or would require the equivalent of institutional or hospital care
  • Any previous treatment with medications used to treat Parkinsonian symptoms or any other neurodegenerative disorder within 1 year before screening even if the patient is taking the medicine for a non-neurodegenerative disorder such as restless leg disorder
  • Typical anti-psychotic or neuroleptic medication within 6 months before screening except as brief treatment for a non-psychiatric indication
  • Antihemostasis medication within 2 weeks before screening
  • Sedative, hypnotic, or benzodiazepine medication within 3 months before screening except intermittent use of the following for sleep or anxiety: alprazolam, lorazepam, oxazepam, temazepam, diazepam, or a short-acting benzodiazepine-like medication

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02353598


Locations
Layout table for location information
United States, Arizona
Mayo Clinic Scottsdale
Phoenix, Arizona, United States, 85054
United States, California
UCSF - Memory and Aging Center
San Francisco, California, United States, 94158
United States, Florida
Brain Matters Research, Inc.
Delray Beach, Florida, United States, 33445
Miami Jewish Health Systems
Miami, Florida, United States, 33137
Bioclinica Orlando
Orlando, Florida, United States, 32806
Bioclinica The Villages
The Villages, Florida, United States, 32162
United States, Indiana
Indiana University School Of Medicine; Department Of Neurology
Indianapolis, Indiana, United States, 46202
United States, Mississippi
Hattiesburg Clinic
Hattiesburg, Mississippi, United States, 39401
United States, Missouri
Millennium Psychiatric Associates, LLC
Saint Louis, Missouri, United States, 63132
United States, New York
Columbia University Medical Center
New York, New York, United States, 10032
UNiversity of Rochester
Rochester, New York, United States, 14620
United States, Rhode Island
Rhode Island Mood & Memory Research Institute
East Providence, Rhode Island, United States, 02914
United States, South Carolina
Roper St. Francis Healthcare; Clinical Biotechnology Research Institute
Charleston, South Carolina, United States, 29401
Sponsors and Collaborators
Genentech, Inc.
Investigators
Layout table for investigator information
Study Director: Clinical Trials Hoffmann-La Roche

Layout table for additonal information
Responsible Party: Genentech, Inc.
ClinicalTrials.gov Identifier: NCT02353598     History of Changes
Other Study ID Numbers: GN29632
First Posted: February 3, 2015    Key Record Dates
Last Update Posted: July 24, 2019
Last Verified: July 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs